<SEC-DOCUMENT>0001104659-20-039599.txt : 20200327
<SEC-HEADER>0001104659-20-039599.hdr.sgml : 20200327
<ACCEPTANCE-DATETIME>20200327161213
ACCESSION NUMBER:		0001104659-20-039599
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20200327
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20200327
DATE AS OF CHANGE:		20200327

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ROCKWELL MEDICAL, INC.
		CENTRAL INDEX KEY:			0001041024
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				383317208
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-23661
		FILM NUMBER:		20751892

	BUSINESS ADDRESS:	
		STREET 1:		411 HACKENSACK AVE., SUITE 501
		CITY:			HACKENSACK
		STATE:			NJ
		ZIP:			07601
		BUSINESS PHONE:		2489609009

	MAIL ADDRESS:	
		STREET 1:		411 HACKENSACK AVE., SUITE 501
		CITY:			HACKENSACK
		STATE:			NJ
		ZIP:			07601

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ROCKWELL MEDICAL TECHNOLOGIES INC
		DATE OF NAME CHANGE:	20120530

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ROCKWELL MEDICAL, INC.
		DATE OF NAME CHANGE:	20120525

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ROCKWELL MEDICAL TECHNOLOGIES INC
		DATE OF NAME CHANGE:	19970722
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>tm2013290d2_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-left: auto; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Washington, D.C. 20549</B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-left: auto; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM&nbsp;8-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CURRENT REPORT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Pursuant to Section&nbsp;13 or 15(d)&nbsp;of</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>the Securities Exchange Act of 1934</B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-left: auto; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Date of Report (Date of earliest event
reported): <B>&nbsp;March 27, 2020</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ROCKWELL MEDICAL,&nbsp;INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact name of registrant as specified
in its charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 33%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Delaware</B></FONT></TD>
    <TD STYLE="width: 34%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>000-23661</B></FONT></TD>
    <TD STYLE="width: 33%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>38-3317208</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(State or other jurisdiction
    <BR>
    of incorporation)</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Commission File
    Number)</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(IRS Employer<BR>
    Identification No.)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>411 Hackensack Avenue, Suite&nbsp;501,
Hackensack, New Jersey 07601</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Address of principal executive offices,
including zip code)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(248) 960-9009</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Registrant&rsquo;s telephone number, including
area code)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Not Applicable</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Former name or former address, if changed
since last report)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-left: auto; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Check the appropriate box below if the Form&nbsp;8-K filing
is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Written
communications pursuant to Rule&nbsp;425 under the Securities Act (17 CFR 230.425)</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Soliciting
material pursuant to Rule&nbsp;14a-12 under the Exchange Act (17 CFR 240.14a-12)</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement
communications pursuant to Rule&nbsp;14d-2(b)&nbsp;under the Exchange Act (17 CFR 240.14d-2(b))</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement
communications pursuant to Rule&nbsp;13e-4(c)&nbsp;under the Exchange Act (17 CFR 240.13e-4(c)</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Securities registered pursuant to Section&nbsp;12(b)&nbsp;of
the Act:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 36%; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Title&nbsp;of&nbsp;Each&nbsp;Class</B></FONT></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 24%; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Trading&nbsp;Symbol</B></FONT></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 36%; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Name&nbsp;of&nbsp;Each&nbsp;exchange&nbsp;on&nbsp;which
    registered</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common Stock, par
    value $0.0001</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">RMTI</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nasdaq Global Market</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule&nbsp;405 of the Securities Act of 1933 (&sect;230.405 of this chapter) or Rule&nbsp;12b-2 of
the Securities Exchange Act of 1934 (&sect;240.12b-2 of this chapter).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">Emerging
growth company&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings">&#168;</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section&nbsp;13(a)&nbsp;of the Exchange
Act. <FONT STYLE="font-family: Wingdings">&#168;</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-left: auto; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; width: 0.85in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><U>Item 8.01</U></B></FONT></TD>
    <TD STYLE="text-align: left"><B><U>Other Events</U>.</B></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">On
March 27, 2020, Rockwell Medical,&nbsp;Inc. issued a press release announcing that the U.S. Food and Drug Administration approved
Triferic&reg; AVNU (ferric pyrophosphate citrate), its intravenous formulation of Triferic for replacement of iron and maintenance
of hemoglobin in hemodialysis patients. </FONT>A copy of the press release is attached hereto as Exhibit 99.1 and incorporated
herein by reference.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; width: 0.85in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Item
    9.01</U></B></FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Financial Statements
    and Exhibits</U></B></FONT><B><FONT STYLE="font-size: 10pt">.</FONT></B></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.85in; text-align: left">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;<I>Exhibits</I>.</FONT></TD>
    <TD STYLE="text-align: left">The following exhibit is being furnished herewith:</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><U>EXHIBIT INDEX</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 0.75in; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit&nbsp;No.</B></FONT></TD>
    <TD STYLE="width: 0.1in; text-align: center">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Description</B></FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; width: 0.85in; text-align: center">&nbsp;</TD></TR>
<TR>
    <TD STYLE="padding-top: 3pt; vertical-align: top"><A HREF="tm2013290d2_ex99-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</FONT></A></TD>
    <TD STYLE="padding-top: 3pt; vertical-align: bottom">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-top: 3pt; vertical-align: top"><A HREF="tm2013290d2_ex99-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Press
    Release, dated March 27, 2020</FONT></A></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><U>SIGNATURE</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ROCKWELL MEDICAL,&nbsp;INC.</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 48%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: March 27, 2020</FONT></TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/&nbsp;Stuart&#8239;Paul</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stuart Paul</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>tm2013290d2_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: right; margin: 0"><B>Exhibit 99.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="image_001.jpg" ALT="ogo" STYLE="height: 60px; width: 286px"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><B>FOR IMMEDIATE RELEASE</B></P>

<P STYLE="text-align: center; font: 14pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Rockwell Medical, Inc. Receives FDA
Approval for Triferic&reg; AVNU (Ferric Pyrophosphate Citrate), Intravenous Formulation of Triferic for Replacement of Iron and
Maintenance of Hemoglobin in Hemodialysis Patients</B></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&ndash; Enhances Triferic platform by providing
patients with greater access to Rockwell Medical&rsquo;s<BR>
 innovative therapeutic by expanding administration options for clinicians
 &ndash;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: center"><FONT STYLE="font-size: 10pt">&ndash;
Major milestone </FONT>supports the potential for expanding global adoption of Triferic and<BR>
 transforming the standard of care
for anemia management in hemodialysis patients &ndash;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: center">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>WIXOM, Mich., </B>March 27, 2020 &ndash; Rockwell Medical,
Inc. (NASDAQ:RMTI) (&ldquo;Rockwell Medical&rdquo; or the &ldquo;Company&rdquo;), a biopharmaceutical company dedicated to transforming
anemia management and improving outcomes for patients around the world, today announced that the U.S. Food and Drug Administration
(&ldquo;FDA&rdquo;) has approved its New Drug Application (&ldquo;NDA&rdquo;) for its intravenous formulation of Triferic, Triferic
AVNU. With this approval, Triferic AVNU joins Triferic Dialysate as the only FDA-approved products indicated to replace iron and
maintain hemoglobin in adult patients with hemodialysis-dependent chronic kidney disease.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Triferic is a novel, physiologic iron maintenance therapy that
provides bioavailable iron to replace iron lost during every dialysis treatment and maintain hemoglobin. While Triferic Dialysate
is designed to be administered via liquid bicarbonate, Triferic AVNU is designed for direct intravenous infusion, which provides
hemodialysis patients with greater access to the Triferic platform and expands administration options for clinicians. Triferic
AVNU can be administered regardless of a dialysis center&rsquo;s mode of bicarbonate delivery. Many dialysis centers in international
markets and an increasing number of dialysis centers in the U.S. have converted to the use of dry bicarbonate cartridges or bags
and on-line dialysate generation, which is not compatible with Triferic Dialysate.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;The
approval of Triferic AVNU is a major milestone as we further progress toward our goal of transforming anemia management across
the globe. With Triferic AVNU, more adult hemodialysis patients in the U.S will have access to the benefits of this unique therapeutic,
regardless of the way their clinic generates bicarbonate. Clinicians will now have the added flexibility to administer Triferic
intravenously to a broader group of patients who can benefit from physiologic iron maintenance therapy to manage their anemia,&rdquo;
</FONT>stated Stuart Paul, President and Chief Executive Officer of Rockwell Medical.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&ldquo;Clinical trials have demonstrated that patients treated
with Triferic receive steady and consistent bioavailable iron to replace the iron that is lost at every dialysis treatment and
hemoglobin is maintained. Now, even in clinics where delivering Triferic through the dialysate is not operationally possible,
Triferic AVNU is an option. This may be especially important for patients who are difficult to manage, or for other special patient
populations,&rdquo; added Dr. Steven Fishbane, Chief of Nephrology of Northwell Health and Professor of Medicine at the Zucker
School of Medicine.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Over the next several months, the Company plans to initiate
a commercial strategy that leverages the experience gained from the 2019 launch of Triferic Dialysate and lays the groundwork
for the commercial introduction of Triferic AVNU. The Company expects to launch Evaluation Programs during the third quarter of
2020 to allow clinics to gain direct experience with Triferic AVNU, and the Company expects Triferic AVNU to be available commercially
following the completion of the initial Evaluation Programs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>About Rockwell Medical</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Rockwell Medical is a biopharmaceutical company dedicated to
transforming anemia management in a wide variety of therapeutic areas and across the globe, improving the lives of very sick patients.
The Company&rsquo;s initial focus is the treatment of anemia in end-stage renal disease (ESRD). Rockwell Medical's exclusive renal
drug therapy, Triferic (ferric pyrophosphate citrate), is the only FDA-approved therapeutic indicated for iron replacement and
maintenance of hemoglobin in hemodialysis patients. Rockwell Medical is also an established manufacturer, supplier and leader
in delivering high-quality hemodialysis concentrates/dialysates to dialysis providers and distributors in the U.S. and abroad.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>About Triferic </B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Triferic is the only FDA-approved therapy in the U.S. indicated
to replace iron and maintain hemoglobin in hemodialysis patients during each dialysis treatment. Triferic has a unique and differentiated
mechanism of action which has the potential to benefit patients and health care economics. Triferic represents a potential innovative
medical advancement in hemodialysis patient iron management&ndash; with the potential to become the future standard of care. The
Company has two FDA-approved formulations of Triferic (1) Triferic Dialysate and (2) Triferic AVNU.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Triferic delivers between 5-7 mg iron with every hemodialysis
treatment to the bone marrow and maintains hemoglobin without increasing iron stores (ferritin). Triferic donates iron immediately
and completely to transferrin (carrier of iron in the body) upon entry into the blood and is then transported directly to the
bone marrow to be incorporated into hemoglobin, with no increase in ferritin (stored iron and inflammation) and no reports of
anaphylaxis in over 1,000,000 patient administrations, addressing a significant medical need in overcoming Functional Iron Deficiency
(FID) in ESRD patients.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Important Safety Information</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Serious hypersensitivity reactions, including anaphylactic-type
reactions, some of which have been life-threatening and fatal, have been reported in patients receiving parenteral iron products.
Patients may present with shock, clinically significant hypotension, loss of consciousness, and/or collapse. Monitor patients
for signs and symptoms of hypersensitivity during and after hemodialysis until clinically stable. Personnel and therapies should
be immediately available for the treatment of serious hypersensitivity reactions. Hypersensitivity reactions have been reported
in 1 (0.3%) of 292 patients receiving Triferic in two randomized clinical trials.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Iron status should be determined on pre-dialysis blood samples.
Post dialysis serum iron parameters may overestimate serum iron and transferrin saturation.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The most common adverse reactions (&ge;3% and at least 1% greater
than placebo) in controlled clinical studies include: procedural hypotension (21.6%), muscle spasms (9.6%), headache (9.2%), pain
in extremity (6.8%), peripheral edema (6.8%), dyspnea (5.8%), back pain (4.5%), pyrexia (4.5%), urinary tract infection (4.5%),
asthenia (4.1%), fatigue (3.8%), arteriovenous (AV) fistula thrombosis (3.4%), and AV fistula site hemorrhage (3.4%).</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Forward-Looking Statements </B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Certain statements in this press release may constitute &ldquo;forward-looking
statements&rdquo; within the meaning of the federal securities laws, including, but not limited to, Rockwell Medical&rsquo;s expectations
regarding the consummation of the offering, the terms of the offering, and the satisfaction of customary closing conditions with
respect to the offering and the anticipated use of the net proceeds of the offering. Words such as &ldquo;may,&rdquo; &ldquo;might,&rdquo;
 &ldquo;will,&rdquo; &ldquo;should,&rdquo; &ldquo;believe,&rdquo; &ldquo;expect,&rdquo; &ldquo;anticipate,&rdquo; &ldquo;estimate,&rdquo;
 &ldquo;continue,&rdquo; &ldquo;could,&rdquo; &ldquo;plan,&rdquo; &ldquo;potential,&rdquo; &ldquo;predict,&rdquo; &ldquo;forecast,&rdquo;
 &ldquo;project,&rdquo; &ldquo;intend&rdquo; or similar expressions, or statements regarding intent, belief, or current expectations,
are forward-looking statements. While Rockwell Medical believes these forward-looking statements are reasonable, undue reliance
should not be placed on any such forward-looking statements, which are based on information available to us on the date of this
release. These forward-looking statements are based upon current estimates and assumptions and are subject to various risks and
uncertainties (including, without limitation, those set forth in Rockwell Medical&rsquo;s SEC filings), many of which are beyond
our control and subject to change. Actual results could be materially different. Risks and uncertainties include: statements about
the issuance of a unique J code for our Triferic powder packet; timing and regulatory approval process for Triferic Dialysate
in China; the potential market and commercialization opportunity of Triferic Dialysate in China upon regulatory approval; the
timing, as well as commercialization opportunity and process for Triferic AVNU; the potential domestic and international market
opportunity for Triferic AVNU, as well as other Rockwell Medical products; CMS&rsquo; announced final rule relating to the eligibility
criteria for TDAPA; liquidity and capital resources; expected duration of Rockwell Medical&rsquo;s existing working capital; the
success of our commercialization of Triferic Dialysate, which commenced in May 2019; and the timing and success of our efforts
to maintain, grow and improve the profit margin of the Company&rsquo;s concentrate business; and the impact of general economic,
industrial or political conditions, as well as recent health conditions in the United States or internationally, as well as those
risks more fully discussed in Rockwell Medical&rsquo;s SEC filings. Accordingly, you should not place undue reliance on these
forward-looking statements. Rockwell Medical expressly disclaims any obligation to update or alter any statements whether as a
result of new information, future events or otherwise, except as required by law.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Triferic&reg; is a registered trademark of Rockwell Medical,
Inc.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Contact<BR>
</B>Investor Relations:<BR>
Lisa M. Wilson, In-Site Communications, Inc.<BR>
T: 212-452-2793<BR>
E: lwilson@insitecony.com</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Source: Rockwell Medical, Inc.</I></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"><I></I></P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ ^@#Z  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  U 1X# 2(  A$! Q$!_\0
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M&GXT+XK\$?LJKK]SJ'CCXQZN'O/B;\;?$]K<_9/%?AWX<>(?$;7-]+)XEO\
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M=L5O@+BYLYTA+A59^#'[<G[&1!!_:Q_9O4^O_"[?AOU]/^1D_49SSS7\Y/\
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M?<Q_P6E_X+/9&?VN_CYC&!CX.>%P0.PY^%OZ8%>[Q?P9F7'F!X-C0S?)L'/
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MA.6?8;AOC-<6*:2G4C#*(TJF7W<I5(MPTJ.SA&#Y'#\9PD>)\FJ?4H\,^/\
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MYH&OQ6\A>T76]'TS5!8_+C-D+VSD6!\@'=DL"3RP 4=8$/?;^9_3@?J*<4]
M/Q)_S^O^-*ES12^K5<;@G';DJ2I-75G:U25KK1VDKK1W"I2H27[RC&MI;WHQ
MF_Q2./T7P?X;\._:/^$?\.Z'H@FWB5M+L;>RFNMR8!FN;:"*2/#=D,I7[RE3
M\M=.L0#;CL!"^6'5"9/+&" 7)W 9YQ\W(SP>ED)Z@?@3_G]?\::4/;;^9_7@
M_H*=;GG=XFKC<=*5N9SJ.K)I;)MSBW;HG*RZ)7=RG2H07[JE&AY1C&'Y)_AY
ME(6[?.)/*D+O&6+-(T;%%P9D@92L$I/58V(. YD9QBL75_"NA:_''#KVBZ-K
MD5O*)K.'6=*T_4X;%P ,V<<UJAA; '[P.9,#&<<5U&UB.0GX9_G@?IBD*O\
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M\3/V0=<OH8Y-2LM'\5?$WQ7IWQCTC4X5TF#2]"U3Q78PQ+=V"6->MA,KGF&
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M^.?$/C7_ (3Q]0\(^%M,:9-9UKQ_<75S%XF6WTVVN+F^UJ6]EW?9;YHY9"&
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>SITK\L7RQ7,J:D[1IP5^:_NK7<X<-&*NTO/\S__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
